Valence8 US LP Purchases Shares of 57,293 Indivior PLC (NASDAQ:INDV)

Valence8 US LP purchased a new position in shares of Indivior PLC (NASDAQ:INDV) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 57,293 shares of the company’s stock, valued at approximately $564,000. Indivior comprises about 0.2% of Valence8 US LP’s portfolio, making the stock its 18th biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in shares of Indivior during the 2nd quarter valued at $188,000. VELA Investment Management LLC acquired a new stake in shares of Indivior in the second quarter valued at about $235,000. XTX Topco Ltd purchased a new stake in shares of Indivior during the 2nd quarter valued at about $249,000. Cubist Systematic Strategies LLC lifted its position in Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after acquiring an additional 6,121 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Indivior in the 1st quarter worth approximately $1,523,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

INDV has been the topic of a number of analyst reports. Craig Hallum dropped their price objective on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, October 11th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th.

Indivior Price Performance

Shares of NASDAQ INDV opened at $10.76 on Friday. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The business has a 50 day moving average price of $9.43 and a two-hundred day moving average price of $12.65. The firm has a market cap of $1.48 billion, a PE ratio of -266.18 and a beta of 0.70.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Sell-side analysts expect that Indivior PLC will post 1.66 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.